Alzheimer's Disease Study Remote Administration

Alzheimer’s Disease studies generally have low success rates so when the COVID-19 pandemic required clinical trials to change to remote administration models, it became more critical than ever to maximize the quantity and quality of data in these studies. Signant Health’s David Miller outlines considerations for optimizing the quality and reliability of remote outcomes assessment data, including:

• Validating scales for audio and/or video administration
• Confirming if input is needed from patient and/or caregiver
• Ensuring all participants understand their roles
• Considering study drug administration
• Meeting site location needs
• Respecting the patient’s discomfort with an at-home administer during COVID-19